The research progress of microRNAs in common liver diseases

doi:10.3877/cma.j.issn.2095-7157.2019.01.007

Abstract

Abstract:

As an important part of epigenetics, microRNAs can regulate about 60% of protein-coding genes in human genome, and participate in the regulation of growth and development, cell proliferation and apoptosis, fat metabolism, viral immunity and so on. So far, a large number of studies have explored the high correlation between abnormally expressed microRNAs and various liver diseases. This article reviews the recent studies on the mechanism and characteristics of microRNAs in viral hepatitis B, non-alcoholic fatty liver disease, liver fibrosis, cirrhosis and hepatocellular carcinoma.

Key words: MicroRNAs, Liver disease, Progress

Shuai Zhang, Yingdi Liu, Guohui Sun, Juan Wang, Zhandi He. The research progress of microRNAs in common liver diseases[J]. Chinese Journal of Gastrointestinal Endoscopy(Electronic Edition), 2019, 06(01): 32-36.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhwcnjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-7157.2019.01.007

https://zhwcnjdzzz.cma-cmc.com.cn/EN/Y2019/V06/I01/32

References 49

[1]	Qian Z, Shen Q, Yang X, et al.The Role of Extracellular Vesicles: An Epigenetic View of the Cancer Microenvironment[J]. Biomed Res Int, 2015, 2015: 649161-649168.
[2]	Slaby O, Svoboda M, Michalek J, et al.MicroRNAs in colorectal cancer: translation of molecular biology into clinical application[J]. Mol Cancer, 2009, 8(1): 102-114.
[3]	Igaz I and Topa L. [Significance of microRNA expression in body fluids in the diagnosis of gastrointestinal tumors][J]. Orv Hetil, 2014, 155(1): 11-15.
[4]	Esteller M. Non-coding RNAs in human disease[J]. Nat Rev Genet, 2011, 12(12): 861-874.
[5]	Dandri M and Locarnini S. New insight in the pathobiology of hepatitis B virus infection[J]. Gut, 2012, 61(Suppl 1): i6-i17.
[6]	Loggi E, Gamal N, Bihl F, et al.Adaptive response in hepatitis B virus infection[J]. J Viral Hepat, 2014, 21(5): 305-313.
[7]	Wang G, Dong F, Xu Z, et al.MicroRNA profile in HBV-induced infection and hepatocellular carcinoma[J]. BMC Cancer, 2017, 17(1): 805-815.
[8]	Xu J, Wu C, Che X, et al.Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis[J]. Mol Carcinog, 2011, 50(2): 136-142.
[9]	Zhang H, Li QY, Guo ZZ, et al.Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B[J]. World J Gastroenterol, 2012, 18(37): 5188-5196.
[10]	Li JF, Dai XP, Zhang W, et al.Upregulation of microRNA-146a by hepatitis B virus X protein contributes to hepatitis development by downregulating complement factor H[J]. MBio, 2015, 6(2): e02459-02464.
[11]	Wang Y, Li Y. miR-146 promotes HBV replication and expression by targeting ZEB2[J]. Biomed Pharmacother, 2018, 99(3): 576-582.
[12]	Xing T, Zhu J, Xian J, et al.miRNA-548ah promotes the replication and expression of hepatitis B virus by targeting histone deacetylase 4[J]. Life Sci, 2019, 219(4): 199-208.
[13]	Nielsen KO, Jacobsen KS, Mirza AH, et al.Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model[J]. Exp Cell Res, 2018, 371(1): 92-103.
[14]	Zhao F, Xu G, Zhou Y, et al.MicroRNA-26b inhibits hepatitis B virus transcription and replication by targeting the host factor CHORDC1 protein[J]. J Biol Chem, 2014, 289(50): 35029-35041.
[15]	Shih C, Chou SF, Yang CC, et al.Control and Eradication Strategies of Hepatitis B Virus[J]. Trends Microbiol, 2016, 24(9): 739-749.
[16]	Wang Y, Tian H. miR-101 suppresses HBV replication and expression by targeting FOXO1 in hepatoma carcinoma cell lines[J]. Biochem Biophys Res Commun, 2017, 487(1): 167-172.
[17]	Chalasani N, Younossi Z, Lavine JE, et al.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 67(1): 328-357.
[18]	Dowman JK, Tomlinson JW, Newsome PN.Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2011, 33(5): 525-540.
[19]	Zheng X, Gong L, Luo R, et al.Serum uric acid and non-alcoholic fatty liver disease in non-obesity Chinese adults[J]. Lipids Health Dis, 2017, 16(1): 202-208.
[20]	Michelotti GA, Machado MV, Diehl AM.NAFLD, NASH and liver cancer[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(11): 656-665.
[21]	Katsura A, Morishita A, Iwama H, et al.MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis[J]. Int J Mol Med, 2015, 35(4): 877-884.
[22]	Afonso MB, Rodrigues PM, Simao AL, et al.Circulating microRNAs as Potential Biomarkers in Non-Alcoholic Fatty Liver Disease and Hepatocellular Carcinoma[J]. J Clin Med, 2016, 5(3): 30-49.
[23]	Hu J, Xu Y, Hao J, et al.MiR-122 in hepatic function and liver diseases[J]. Protein Cell, 2012, 3(5): 364-371.
[24]	Liu CH, Ampuero J, Gil-Gomez A, et al.miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. J Hepatol, 2018, 69(6): 1335-1348.
[25]	Clarke JD, Sharapova T, Lake AD, et al.Circulating microRNA 122 in the methionine and choline-deficient mouse model of non-alcoholic steatohepatitis[J]. J Appl Toxicol, 2014, 34(6): 726-732.
[26]	Pirola CJ, Fernandez Gianotti T, Castano GO, et al.Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis[J]. Gut, 2015, 64(5): 800-812.
[27]	Wu GY, Rui C, Chen JQ, et al.MicroRNA-122 Inhibits Lipid Droplet Formation and Hepatic Triglyceride Accumulation via Yin Yang 1[J]. Cell Physiol Biochem, 2017, 44(4): 1651-1664.
[28]	Management of liver cirrhosis[J]. Lancet, 2014, 383(9930): 1694-1694.
[29]	Heidelbaugh JJ and Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation[J]. Am Fam Physician, 2006, 74(5): 756-762.
[30]	Ganem D and Prince AM.Hepatitis B virus infection-natural history and clinical consequences[J]. N Engl J Med, 2004, 350(11): 1118-1129.
[31]	Guo L, Li W, Hu L, et al.Diagnostic value of circulating microRNAs for liver cirrhosis: a meta-analysis[J]. Oncotarget, 2018, 9(4): 5397-5405.
[32]	Lopez-Riera M, Conde I, Quintas G, et al.Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers[J]. Sci Rep, 2018, 8(1): 10606.
[33]	Riazalhosseini B, Mohamed R, Apalasamy YD, et al.Circulating microRNA as a marker for predicting liver disease progression in patients with chronic hepatitis B[J]. Rev Soc Bras Med Trop, 2017, 50(2): 161-166.
[34]	Shaheen NMH, Zayed N, Riad NM, et al.Role of circulating miR-182 and miR-150 as biomarkers for cirrhosis and hepatocellular carcinoma post HCV infection in Egyptian patients [J]. Virus Res, 2018, 255(16): 77-84.
[35]	Yan G, Li B, Xin X, et al.MicroRNA-34a Promotes Hepatic Stellate Cell Activation via Targeting ACSL1[J]. Med Sci Monit, 2015, 21(10): 3008-3015.
[36]	Fernandez-Ramos D, Fernandez-Tussy P, Lopitz-Otsoa F, et al. MiR-873-5p acts as an epigenetic regulator in early stages of liver fibrosis and cirrhosis[J]. Cell Death Dis, 2018, 9(10): 958-973.
[37]	Farrar C, Clarke S. Altered levels of S-adenosylmethionine and S-adenosylhomocysteine in the brains of L-isoaspartyl (D- Aspartyl) O-methyltransferase-deficient mice[J]. J Biol Chem, 2002, 277(31): 27856-27863.
[38]	Ma L, Ma J, Ou HL.MicroRNA219 overexpression serves a protective role during liver fibrosis by targeting tumor growth factor beta receptor 2[J]. Mol Med Rep, 2019, 19(3): 1543-1550.
[39]	Shen J, Huang CK, Yu H, et al.The role of exosomes in hepatitis, liver cirrhosis and hepatocellular carcinoma[J]. J Cell Mol Med, 2017, 21(5): 986-992.
[40]	Miller KD, Siegel RL, Lin CC, et al.Cancer treatment and survivorship statistics, 2016[J]. CA Cancer J Clin, 2016, 66(4): 271-289.
[41]	El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma[J]. Gastroenterology, 2012, 142(6): 1264-1273.e1.
[42]	Yang JD, Roberts LR.Hepatocellular carcinoma: A global view[J]. Nat Rev Gastroenterol Hepatol, 2010, 7(8): 448-458.
[43]	Abdalla MA, Haj-Ahmad Y. Promising Candidate Urinary MicroRNA Biomarkers for the Early Detection of Hepatocellular Carcinoma among High-Risk Hepatitis C Virus Egyptian Patients [J]. J Cancer, 2012, 3(1): 19-31.
[44]	Peng C, Ye Y, Wang Z, et al.Meta-analysis of circulating microRNAs for the diagnosis of hepatocellular carcinoma[J]. Dig Liver Dis, 2018, 卷(期): 起-止页.
[45]	Ye Y, Song Y, Zhuang J, et al.MicroRNA-302a-3p suppresses hepatocellular carcinoma progression by inhibiting proliferation and invasion[J]. Onco Targets Ther, 2018, 11: 8175-8184.
[46]	Bai S, Nasser MW, Wang B, et al.MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib[J]. J Biol Chem, 2009, 284(46): 32015-32027.
[47]	Xiong Y, Fang JH, Yun JP, et al.Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma[J]. Hepatology, 2010, 51(3): 836-845.
[48]	Zhang P, Yin J, Yuan L, et al.MicroRNA-139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I[J]. Oncol Lett, 2019, 17(2): 1903-1913.
[49]	Ni JS, Zheng H, Huang ZP, et al.MicroRNA-197-3p acts as a prognostic marker and inhibits cell invasion in hepatocellular carcinoma[J]. Oncol Lett, 2019, 17(2): 2317-2327.

Please choose a citation manager

Content to export